TY - JOUR
T1 - Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis
AU - Nakamura, Minoru
AU - Shimizu-Yoshida, Yuki
AU - Takii, Yasushi
AU - Komori, Atsumasa
AU - Yokoyama, Terufumi
AU - Ueki, Toshihito
AU - Daikoku, Manabu
AU - Yano, Koji
AU - Matsumoto, Takehiro
AU - Migita, Kiyoshi
AU - Yatsuhashi, Hiroshi
AU - Ito, Masahiro
AU - Masaki, Naohiko
AU - Adachi, Hiroshi
AU - Watanabe, Yukio
AU - Nakamura, Yoko
AU - Saoshiro, Takeo
AU - Sodeyama, Takeshi
AU - Koga, Michiaki
AU - Shimoda, Shinji
AU - Ishibashi, Hiromi
N1 - Funding Information:
The authors thank Drs Eeichi Takezaki, Tatsuji Komatsu, Takehiro Sando, Masaaki Shimada, Akihide Masumoto, Toyokichi Muro, Shigeki Hayashi, Yukio Ohara, Hideharu Harada, Kazuhiro Sugi, Masakazu Kobayashi, Yutaka Mano, Hideo Morimoto, Shin Tanaka, Tetsuo Yamamoto, Yasushi Uchida, Michio Kato, Taizo Hijioka, Hironori Sakai, Hidehiro Nishi in National Hospital Organization Study Group for Liver Disease in Japan NHOSLJ for providing serum samples of PBC patients. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan, Grants-in-aid for Scientific Research from Japan Society for the Promotion of Science and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
PY - 2005/3
Y1 - 2005/3
N2 - Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
AB - Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
UR - http://www.scopus.com/inward/record.url?scp=13844289482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13844289482&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2004.11.016
DO - 10.1016/j.jhep.2004.11.016
M3 - Article
C2 - 15710222
AN - SCOPUS:13844289482
VL - 42
SP - 386
EP - 392
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 3
ER -